SMC endorses five new therapies for NHS Scotland
Scottish cost regulators have approved funding for five new therapies on the NHS, offering new treatment options for a range of conditions.
Read More
Tag: Epclusa
Darzalex, Epclusa will be funded on NHS Scotland
Patients in Scotland with multiple myeloma and those with some types of hepatitis C have won NHS access to new treatment options after the Scottish Medicines Consortium backed routine use of Janssen’s Darzalex and Gilead’s Epclusa.
Read More
Final yes from NICE for Gilead’s Epclusa
The National Institute for Health and Care Excellence has now published final guidance endorsing Epclusa as an option for the treatment of adults with chronic hepatitis C genotype 1-6 infection on the NHS in England and Wales.
Read More
SMC endorses use of five meds on NHS Scotland
The Scottish Medicines Consortium has endorsed the use of five new therapies by NHS Scotland to treat melanoma, ovarian cancer, hepatitis C, Fabry disease and bacterial vaginosis.
Read More
NICE clears Gilead’s pan-genotypic hep C drug Epclusa
The National Institute for Health and Care Excellence is endorsing Gilead’s pan-genotypic hepatitis C drug Epclusa for routine NHS use in England and Wales.
Read More
EU clears Gilead’s pan-genotypic hepatitis C therapy
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by European regulators to treat all six types of the virus, potentially eliminating the need for genotype testing.
Read More
US clears Gilead’s pan-genotypic hepatitis C therapy
Gilead’s Sovaldi-based combination therapy for hepatitis C has been cleared for use by the US Food and Drug Administration to treat all six types of the virus, potentially eliminating the need for genotype testing.
Read More
Six medicines win backing for EU approval
Six medicines, including two new combination therapies for chronic hepatitis C, are lining up for EU approval after having been recommended by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read More
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
- Ondine’s Steriwave phase 3 trial reaches 93% enrolment milestone
- Arvinas reports strong phase 1 results for ARV-102 in Parkinson’s disease
